The lead product candidate IMM-1-104, a dual-MEK inhibitor, is in Phase 1/2a clinical trial for treating patients with cancer including pancreatic, melanoma, and non-small cell lung cancer caused by RAS and/or RAF mutations. Recent Phase 2a data announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib combined with mGnP.
Cyborg Score Rationale
Immuneering has received an average recommendation of 'Moderate Buy' from seven analysts, with five buy ratings, one strong buy, and one sell. The company has a market cap of $338.35 million but is unprofitable with negative earnings. Strong clinical data provides optionality, but clinical-stage risk remains elevated.
Top Insights
Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer with atebimetinib plus mGnP combination in Phase 2a
Uses proprietary RABIT platform leveraging artificial intelligence for drug design and optimization
Average 1-year analyst price target is $16.50, implying 215% upside from current levels
Company has 66 employees as of January 2026, indicating lean clinical-stage operation
Named Competitors
RAS-targeted therapies — RAS inhibitor platform for oncology
MEK inhibitors — Established MEK inhibitor development
AI-driven drug discovery — AI-powered oncology platform
Recent Developments
(February 2026) Upgraded to Strong Buy rating due to positive Phase 2a data for atebimetinib in first-line RAS-mutant pancreatic cancer
(December 2025) Announced updated Phase 2a trial data with 86% overall survival at 9 months in pancreatic cancer patients
(August 2025) Entered into strategic partnership with Sanofi; obtained new U.S. composition of matter patent providing exclusivity into 2042
Open the full interactive Immuneering Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.